-
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2022/04/05/US11292796B2/abs.jpg.150x150.jpg)
公开(公告)号：US11292796B2
公开(公告)日：2022-04-05
申请号：US16865512
申请日：2020-05-04
发明人： Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
IPC分类号： C07D487/04 , C07D498/14 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14
摘要： Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III) with a compound of the following formula: R1-Y, in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R4, Y, the palladium catalyst and the base are as defined herein.
-
2.发明授权Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith 有权取代的二氨基嘧啶基化合物，其组合物及其处理方法公开(公告)号：US09556126B2
公开(公告)日：2017-01-31
申请号：US14576197
申请日：2014-12-19
发明人： Patrick Papa , Brian Edwin Cathers , Andrew Antony Calabrese , Brandon Wade Whitefield , Brydon Bennett , Daniel Cashion , Deborah Mortensen , Dehua Huang , Eduardo Torres , Jason Parnes , John Sapienza , Joshua Hansen , Katerina Leftheris , Matthew Correa , Maria Mercedes Delgado , Raj K. Raheja , Sogole Bahmanyar , Sayee Hegde , Stephen Norris , Veronique Plantevin-Krenitsky
IPC分类号： C07D403/12 , A61K31/505 , C07D239/48 , C07D401/12 , C07D409/12 , C07D413/12 , C07D405/12 , C07D471/04 , C07D405/14 , A61K31/506 , C07D417/12
CPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
摘要翻译： 本文提供具有以下结构的二氨基嘧啶化合物：其中X，L，R 1和R 2如本文所定义，包含有效量的二氨基嘧啶基化合物的组合物，以及用于治疗或预防PKC-θ介导的病症的方法或病症 可通过抑制激酶例如PKC-θ治疗或预防。
-
![PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY](/abs-image/US/2013/10/31/US20130289271A1/abs.jpg.150x150.jpg)
公开(公告)号：US20130289271A1
公开(公告)日：2013-10-31
申请号：US13927255
申请日：2013-06-26
发明人： Sophie Perrin-Ninkovic , Roy L. Harris , John Sapienza , Graziella I. Shevlin , Patrick Papa , Branden Lee , Garrick Packard , Lida Tehrani , Jingjing Zhao , Jennifer Riggs , Jason Parnes , Deborah Mortensen , Weiming Xu , Loui Madakamutil , Kimberly Elizabeth Fultz , Rama Narla , Sabita Sankar , Jan Elsner
IPC分类号： C07D487/04 , C07D498/14
CPC分类号： C07D487/04 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14 , C07D498/14
摘要： Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
-
4.发明授权公开(公告)号：US09783505B2
公开(公告)日：2017-10-10
申请号：US15241232
申请日：2016-08-19
发明人： Patrick Papa , Brian Edwin Cathers , Andrew Antony Calabrese , Brandon Wade Whitefield , Brydon Bennett , Daniel Cashion , Deborah Mortensen , Dehua Huang , Eduardo Torres , Jason Parnes , John Sapienza , Joshua Hansen , Katerina Leftheris , Matthew Correa , Maria Mercedes Delgado , Raj K. Raheja , Sogole Bahmanyar , Sayee Hegde , Stephen Norris , Veronique Plantevin-Krenitsky
IPC分类号： A61K31/505 , C07D239/48 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D405/12 , C07D471/04 , C07D405/14 , A61K31/506 , C07D417/12 , A61K31/5377
CPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
-
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2017/09/26/US09771371B2/abs.jpg.150x150.jpg)
公开(公告)号：US09771371B2
公开(公告)日：2017-09-26
申请号：US14874524
申请日：2015-10-05
发明人： Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
IPC分类号： C07D487/04 , C07D498/14 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14
CPC分类号： C07D487/04 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14 , C07D498/14
摘要： Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
-
6.发明申请公开(公告)号：US20160354374A1
公开(公告)日：2016-12-08
申请号：US15241232
申请日：2016-08-19
发明人： Patrick Papa , Brian Edwin Cathers , Andrew Antony CALABRESE , Brandon Wade WHITEFIELD , Brydon BENNETT , Daniel CASHION , Deborah MORTENSEN , Dehua HUANG , Eduardo TORRES , Jason PARNES , John SAPIENZA , Joshua HANSEN , Katerina LEFTHERIS , Matthew CORREA , Maria Mercedes DELGADO , Raj K. RAHEJA , Sogole BAHMANYAR , Sayee HEGDE , Stephen NORRIS , Veronique PLANTEVIN-KRENITSKY
IPC分类号： A61K31/506 , A61K31/5377 , A61K31/505
CPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
-
公开(公告)号：US09079900B2
公开(公告)日：2015-07-14
申请号：US14174896
申请日：2014-02-07
发明人： Roy L. Harris , John Sapienza , Graziella Shevlin , Patrick Papa , Branden Gingsee Lee , Garrick Packard , Jingjing Zhao , Patrick Anthony Jokiel , Deborah Mortensen , Jennifer Riggs , Juan Antonio Gamboa , Marie Georges Beauchamps , Matthew Michael Kreilein , Mohit Atul Kothare , Sophie Perrin-Ninkovic , Philip Pye , William Wei-Hwa Leong , Jan Elsner , Anusuya Choudhury
IPC分类号： A61K31/497 , C07D241/00 , C07D471/04 , C07D487/04 , C07D498/14 , C07D519/00
CPC分类号： C07D471/04 , C07D241/20 , C07D487/04 , C07D498/14 , C07D519/00
摘要： Provided herein are methods to prepare Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein. The Heteroaryl compounds are useful for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions.
摘要翻译： 本文提供了制备具有以下结构的杂芳基化合物的方法：其中R 1 -R 4如本文所定义。 杂芳基化合物可用于治疗或预防癌症，炎症状况，免疫学条件，神经变性疾病，糖尿病，肥胖症，神经障碍，年龄相关疾病或心血管疾病。
-
8.发明申请公开(公告)号：US20150175557A1
公开(公告)日：2015-06-25
申请号：US14576197
申请日：2014-12-19
发明人： Patrick Papa , Brian Edwin Cathers , Andrew Antony CALABRESE , Brandon Wade WHITEFIELD , Brydon BENNETT , Daniel CASHION , Deborah MORTENSEN , Dehua HUANG , Eduardo TORRES , Jason PARNES , John SAPIENZA , Joshua HANSEN , Katerina LEFTHERIS , Matthew CORREA , Maria Mercedes DELGADO , Neil RAHEJA , Sami BAHMANYAR , Sayee HEGDE , Stephen NORRIS , Veronique PLANTEVIN-KRENITSKY
IPC分类号： C07D239/48 , C07D403/12 , C07D405/14 , C07D413/12 , C07D405/12 , C07D471/04 , C07D401/12 , C07D409/12
CPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
-
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2014/12/09/US08907087B2/abs.jpg.150x150.jpg)
9.发明授权公开(公告)号：US08907087B2
公开(公告)日：2014-12-09
申请号：US13927255
申请日：2013-06-26
发明人： Sophie Perrin-Ninkovic , Roy L. Harris , John Sapienza , Graziella I. Shevlin , Patrick Papa , Branden Lee , Garrick Packard , Jingjing Zhao , Jennifer Riggs , Jason Parnes , Deborah Mortensen , Jan Elsner
IPC分类号： C07D241/38 , C07D498/14 , C07D487/04
CPC分类号： C07D487/04 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14 , C07D498/14
摘要： Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof. Furthermore, provided are methods of preparing a compound of formula (III), Furthermore, provided are methods of preparing a compound of formula (VI),
摘要翻译： 本文提供具有以下结构的杂芳基化合物：其中R 1 -R 4如本文所定义，包含有效量的杂芳基化合物的组合物以及用于治疗或预防癌症，炎症状况，免疫学条件，神经变性疾病，糖尿病，肥胖症，神经系统疾病 疾病，年龄相关疾病或心血管疾病，包括向有需要的患者施用有效量的杂芳基化合物。 此外，提供制备式（III）化合物的方法。此外，提供制备式（VI）化合物的方法，
-
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2019/01/01/US10167290B2/abs.jpg.150x150.jpg)
公开(公告)号：US10167290B2
公开(公告)日：2019-01-01
申请号：US15680688
申请日：2017-08-18
发明人： Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
IPC分类号： C07D487/04 , C07D498/14 , C07D241/20 , C07D471/04 , C07D471/14 , C07D487/10 , C07D487/14
摘要： Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.04 秒)
